首页> 外文期刊>CNS drugs >Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date
【24h】

Targeting Retinoid Receptors to Treat Schizophrenia: Rationale and Progress to Date

机译:靶向类维生素A受体治疗精神分裂症:理由和迄今为止的进展。

获取原文
获取原文并翻译 | 示例
           

摘要

This review provides the rationale and reports on the progress to date regarding the targeting of retinoid receptors for the treatment of schizophrenia and schizoaffective disorder and the role of retinoic acid in functions of the normal brain, and in psychotic states. After a brief introduction, we describe the normal function of retinoic acid in the brain. We then examine the evidence regarding retinoid dysregulation in schizophrenia. Finally, findings from two add-on clinical trials with a retinoid (bexarotene) are discussed. The authors of this review suggest that targeting retinoid receptors may be a novel approach to treat schizophrenia and schizoaffective disorder. Further studies are warranted.
机译:这篇综述提供了关于以类维生素A受体为靶点治疗精神分裂症和精神分裂症以及维甲酸在正常脑功能和精神病状态中的作用的最新理论和报告。简单介绍之后,我们描述了维甲酸在大脑中的正常功能。然后,我们检查了有关精神分裂症中类维生素A失调的证据。最后,讨论了两项关于类维生素A(贝沙罗汀)的附加临床试验的发现。这篇综述的作者建议靶向类维生素A受体可能是治疗精神分裂症和精神分裂症的一种新颖方法。值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号